Pulsed electromagnetic field therapy to preserve muscle in men on ADT
Official title: A Prospective Randomized Study to Investigate the Effect of Pulsed Electromagnetic Field Therapy on Muscle Mass and Muscle Strength in Prostate Cancer Patients Treated With Androgen Deprivation Therapy
Run by Chinese University of Hong Kong · NCT07057375 · Data updated 2026-11-12
This program will test whether weekly pulsed electromagnetic field therapy applied to the thighs can increase muscle mass and strength in men with non‑metastatic prostate cancer who are receiving androgen deprivation therapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 110 (estimated) |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Shatin) |
| Status | Recruiting |
| Started | June 1, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | March 31, 2027 |
| Registry record updated | October 22, 2026 |
| Trial ID | NCT07057375 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Men aged 18 or older with histologically confirmed non‑metastatic prostate cancer who have been on ADT for 6 months to 3 years, are ambulatory (can walk 400 m), and plan to continue ADT for at least six more months are eligible.
✕Probably not a fit
People with distant metastatic disease, active radiotherapy, amputated lower limbs or other lower‑limb deformities, inability to walk 400 m, or those outside the specified ADT duration are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, parallel-group trial compares active pulsed electromagnetic field (PEMF) therapy using the BIXEPS system to a sham treatment in men with non‑metastatic prostate cancer on androgen deprivation therapy (ADT). Participants receive one 10‑minute PEMF session per lower limb each week for 12 weeks, with limbs treated alternately. Outcomes include body composition and muscle function testing, patient questionnaires, and blood and urine measurements of inflammation and cytokines collected at baseline, week 5, and week 12. Safety and tolerability will also be monitored throughout the study.
Why it matters
Potential benefit: If effective, this approach could help preserve or increase muscle mass and strength in men on ADT, potentially improving mobility and quality of life.
How similar studies have gone: Some preclinical and small clinical studies suggest PEMF can affect muscle and inflammation, but controlled evidence for reversing ADT‑related muscle loss is limited, making this application relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients with age greater than or equal to 18 years old. * Histologically documented PCa * No evidence of distant metastasis (M1 disease) * With ADT exposure from six months to three years * Expected to continue for at least six months * At least four weeks after radical prostatectomy or completed radiotherapy Exclusion Criteria: * Patients are still under active treatment, such as radiotherapy * Patients who are unable to walk for 400 m or undertake exercise that will affect the clinical assessment of muscle strength * Patients with amputated lower limbs or other body deformities that will affect the treatment protocol
Where it's running
-
Prince of Wales Hospital
Shatin, Hong Kong Recruiting
Study contacts
- Principal investigator: Chi Fai NG, MD — Chinese University of Hong Kong
- Study coordinator: Chi Fai NG, MD
- Email: ngcf@surgery.cuhk.edu.hk
- Phone: 3505 2625
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519
This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.
-
PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer
This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.
-
Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer
This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.
-
Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer
This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.
-
Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence
This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.
-
Lutetium-177 Ludotadipep for advanced prostate cancer
This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.